Strides Pharma Science Limited
NSE: STAR BSE: STAR
NSE
796.25
-68.35 (-7.91%)
Prev Close
864.6
Open Price
864.6
Volume
356,395
Today Low / High
791 / 864.65
52 WK Low / High
513.05 / 1025
Range
756 - 836
BSE
796.20
-68.60 (-7.93%)
Prev Close
864.8
Open Price
862.7
Volume
22,244
Today Low / High
793 / 862.7
52 WK Low / High
530.7 / 1024.9
Range
756 - 836
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 796.25 (target range: 756 - 836), reflecting a change of -68.35 (-7.90539%). On the BSE, it is listed at 796.2 (target range: 756 - 836), showing a change of -68.6 (-7.93247%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
23 Jan
864.60
-7.91%
22 Jan
843.00
2.56%
21 Jan
858.90
-3.96%
20 Jan
875.00
-1.75%
19 Jan
900.10
-3.44%
16 Jan
932.00
-3.42%
14 Jan
925.50
1.57%
13 Jan
940.00
-1.44%
12 Jan
941.85
-1.18%
09 Jan
969.05
-2.81%
08 Jan
975.00
-0.72%
07 Jan
977.95
-0.08%
06 Jan
945.90
4.14%
05 Jan
896.35
6.06%
02 Jan
910.00
-1.02%
01 Jan
906.35
0.55%
31 Dec
917.00
-1.82%
30 Dec
899.00
1.01%
29 Dec
912.45
-1.99%
Strides Pharma Science Limited Graph
Strides Pharma Science Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Strides Pharma Science Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 796.25, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 796.20 | 804.16 | 723.75 - 884.58 |
| 812.12 | 649.70 - 974.55 | ||
| 820.09 | 574.06 - 1,066.11 | ||
| Bearish Scenario | 796.20 | 788.24 | 709.41 - 867.06 |
| 780.28 | 624.22 - 936.33 | ||
| 772.31 | 540.62 - 1,004.01 |
Overview of Strides Pharma Science Limited
ISIN
INE939A01011
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
553,753
Market Cap
73,392,523,523
Last Dividend
4
Official Website
IPO Date
2002-06-26
DCF Diff
265.75
DCF
531
Financial Ratios Every Investor Needs
Stock Dividend of STAR
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-22 | July 22, 25 | 4 | 4 | 2025-07-22 | 2025-09-06 | |
| 2024-09-09 | September 09, 24 | 2.5 | 2.5 | 2024-09-09 | 2024-10-25 | |
| 2023-08-04 | August 04, 23 | 1.5 | 1.5 | 2023-08-04 | 2023-09-27 | |
| 2021-08-05 | August 05, 21 | 2.5 | 2.5 | 2021-08-06 | 2021-10-03 | |
| 2020-07-24 | July 24, 20 | 2 | 2 | 2020-07-27 | 2020-09-19 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4,624.06 Cr | 1,979.97 Cr | 2,644.09 Cr | 0.5718 | 0.00 Cr | 878.37 Cr | 1,781.33 Cr | 3,593.46 Cr | 44.05 | 861.53 Cr | 0.7771 |
| 2024-03-31 | 3,828.21 Cr | 2,977.32 Cr | 850.89 Cr | 0.2223 | 0.00 Cr | 155.99 Cr | 301.84 Cr | -70.61 Cr | -7.76 | 439.40 Cr | -0.0184 |
| 2023-03-31 | 3,668.10 Cr | 2,863.00 Cr | 805.11 Cr | 0.2195 | 71.60 Cr | 746.43 Cr | 123.61 Cr | -221.20 Cr | -24.56 | 502.73 Cr | -0.0603 |
| 2022-03-31 | 3,070.25 Cr | 1,613.61 Cr | 1,456.64 Cr | 0.4744 | 98.35 Cr | 151.21 Cr | -251.95 Cr | -460.21 Cr | -51.28 | -134.56 Cr | -0.1499 |
| 2021-03-31 | 3,280.27 Cr | 2,321.10 Cr | 959.17 Cr | 0.2924 | 115.46 Cr | 115.13 Cr | 314.95 Cr | 268.44 Cr | 28.40 | 725.04 Cr | 0.0818 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 136.78 Cr | 6,048.73 Cr | 3,462.26 Cr | 2,551.8310 Cr | 1,879.63 Cr | 1,742.85 Cr | 1,277.57 Cr | 980.34 Cr | 30.05 Cr | 0.00 Cr | 339.71 Cr | 2,591.5180 Cr |
| 2024-03-31 | 161.02 Cr | 5,839.76 Cr | 3,768.05 Cr | 2,125.5630 Cr | 2,516.87 Cr | 2,355.85 Cr | 1,126.24 Cr | 977.30 Cr | 26.04 Cr | 0.00 Cr | 72.97 Cr | 2,879.2590 Cr |
| 2023-03-31 | 303.50 Cr | 6,638.42 Cr | 4,465.54 Cr | 2,212.2580 Cr | 3,029.57 Cr | 2,726.07 Cr | 1,146.51 Cr | 1,372.55 Cr | 32.45 Cr | 0.00 Cr | 459.00 Cr | 2,990.2010 Cr |
| 2022-03-31 | 170.73 Cr | 6,975.86 Cr | 4,592.55 Cr | 2,359.2280 Cr | 3,025.03 Cr | 2,854.30 Cr | 1,173.80 Cr | 1,513.64 Cr | 28.12 Cr | 0.00 Cr | 563.52 Cr | 3,411.6750 Cr |
| 2021-03-31 | 125.83 Cr | 7,015.02 Cr | 4,201.02 Cr | 2,776.6610 Cr | 2,348.23 Cr | 2,222.39 Cr | 1,200.70 Cr | 1,499.45 Cr | 239.96 Cr | 0.00 Cr | 462.94 Cr | 2,738.3480 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 684.3740 Cr | -89.6890 Cr | -642.5810 Cr | 441.8760 Cr | -48.4560 Cr | 112.5640 Cr | -242.4980 Cr | 405.3480 Cr | -351.7940 Cr | -22.9900 Cr | -217.0200 Cr |
| 2024-03-31 | 701.0650 Cr | -150.2500 Cr | -693.3230 Cr | 582.9140 Cr | -142.4810 Cr | 161.0200 Cr | -118.1510 Cr | -62.7240 Cr | -384.4560 Cr | -13.5170 Cr | 30.7040 Cr |
| 2023-03-31 | 44.4110 Cr | 302.4740 Cr | -213.9210 Cr | -50.5270 Cr | 132.7710 Cr | 303.5010 Cr | -94.9380 Cr | -267.6310 Cr | 24.9280 Cr | 0.0000 Cr | -8.1380 Cr |
| 2022-03-31 | -257.8150 Cr | -118.7330 Cr | 421.3160 Cr | -401.1980 Cr | 44.8960 Cr | 170.7300 Cr | -143.3830 Cr | -652.5130 Cr | 638.9630 Cr | -22.4310 Cr | 28.1860 Cr |
| 2021-03-31 | 481.4370 Cr | -520.8210 Cr | -15.7960 Cr | 183.9530 Cr | -56.4000 Cr | 125.8340 Cr | -297.4840 Cr | 289.3800 Cr | 174.9380 Cr | -17.9150 Cr | -414.0490 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 1,220.83 Cr | 791.69 Cr | 429.15 Cr | 0.3515 | 181.92 Cr | 127.53 Cr | 13.84 | 249.94 Cr | 0.1045 |
| 2025-06-30 | 1,119.74 Cr | 718.69 Cr | 401.05 Cr | 0.3582 | 169.19 Cr | 99.61 Cr | 10.81 | 218.29 Cr | 0.0890 |
| 2025-03-31 | 1,190.39 Cr | 770.69 Cr | 419.70 Cr | 0.3526 | 169.01 Cr | 82.19 Cr | 8.92 | 229.05 Cr | 0.0690 |
| 2024-12-31 | 1,153.67 Cr | 480.12 Cr | 673.54 Cr | 0.5838 | 161.89 Cr | 87.95 Cr | 9.56 | 214.45 Cr | 0.0762 |
| 2024-09-30 | 1,201.11 Cr | 767.86 Cr | 433.25 Cr | 0.3607 | 185.28 Cr | 93.23 Cr | 10.14 | 247.54 Cr | 0.0776 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 142.85 Cr | 84.61 Cr | 227.46 Cr | 1,143.79 Cr | 1,459.49 Cr | 3,313.18 Cr | 1,046.49 Cr | 6,520.58 Cr | 3,717.82 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 198.62 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -2,586.46 Cr |
| 2025-03-31 | 136.78 Cr | 86.06 Cr | 206.28 Cr | 1,202.94 Cr | 1,277.57 Cr | 3,098.91 Cr | 980.34 Cr | 6,048.73 Cr | 3,462.26 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 246.99 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -2,215.00 Cr |
| 2024-09-30 | 175.51 Cr | 71.48 Cr | 246.99 Cr | 1,246.87 Cr | 1,210.60 Cr | 3,094.02 Cr | 998.77 Cr | 5,989.63 Cr | 3,774.63 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 99.61 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 82.19 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 87.95 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 93.23 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 70.20 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,631.90 | ₹3,915,474,737,543.00 | ₹1,678,650.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,011.50 | ₹1,595,864,368,670.00 | ₹460,453.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,932.20 | ₹1,330,835,159,168.00 | ₹315,832.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,235.60 | ₹1,028,721,212,318.00 | ₹3,888,844.00 |
| Lupin Limited | LUPIN | ₹2,137.20 | ₹976,270,408,183.00 | ₹578,346.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹882.00 | ₹887,498,379,180.00 | ₹460,318.00 |
| Mankind Pharma Limited | MANKIND | ₹2,107.60 | ₹870,027,969,747.00 | ₹406,697.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,750.50 | ₹687,558,532,500.00 | ₹77,302.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,132.50 | ₹657,757,838,048.00 | ₹511,822.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,967.70 | ₹555,286,531,869.00 | ₹424,174.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,016.40 | ₹548,710,229,945.00 | ₹4,200,664.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,462.80 | ₹371,118,530,090.00 | ₹47,635.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,699.60 | ₹337,276,210,550.00 | ₹73,196.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,530.80 | ₹290,197,644,232.00 | ₹138,093.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,846.00 | ₹289,177,746,000.00 | ₹132,465.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,351.60 | ₹219,624,415,620.00 | ₹259,357.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,319.00 | ₹207,975,000,000.00 | ₹5,165.00 |
| Eris Lifesciences Limited | ERIS | ₹1,385.60 | ₹188,742,124,170.00 | ₹94,274.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,251.00 | ₹170,008,859,139.00 | ₹26,149.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹956.10 | ₹151,417,316,063.00 | ₹139,597.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹764.55 | ₹150,282,336,454.00 | ₹22,821.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹831.95 | ₹149,010,456,347.00 | ₹318,008.00 |
| Cohance Lifesciences Limited | COHANCE | ₹381.60 | ₹145,987,620,624.00 | ₹380,203.00 |
| Granules India Limited | GRANULES | ₹565.00 | ₹137,107,824,540.00 | ₹972,146.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,723.00 | ₹130,968,152,208.00 | ₹65,701.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹883.50 | ₹108,388,663,500.00 | ₹208,914.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,395.50 | ₹89,561,965,581.00 | ₹32,077.00 |
| Strides Pharma Science Limited | STAR | ₹796.25 | ₹73,392,523,523.00 | ₹356,395.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹768.70 | ₹69,680,574,898.00 | ₹277,301.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹424.80 | ₹65,037,754,238.00 | ₹81,217.00 |
| FDC Limited | FDC | ₹369.60 | ₹60,174,607,046.00 | ₹49,065.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹267.00 | ₹52,220,344,872.00 | ₹242,372.00 |
| Sequent Scientific Limited | SEQUENT | ₹201.37 | ₹50,307,022,432.00 | ₹364,240.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.94 | ₹40,545,727,205.00 | ₹476,606.00 |
| Innova Captab Limited | INNOVACAP | ₹678.05 | ₹38,801,363,108.00 | ₹1,793,841.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,135.70 | ₹35,322,374,336.00 | ₹4,017.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹688.40 | ₹34,915,031,882.00 | ₹42,892.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹317.80 | ₹34,629,161,217.00 | ₹174,725.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹370.05 | ₹33,774,463,500.00 | ₹102,103.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹309.70 | ₹31,057,492,108.00 | ₹32,969.00 |
| Suven Life Sciences Limited | SUVEN | ₹134.07 | ₹30,497,439,180.00 | ₹248,500.00 |
Key Executives
Executive Director of Business Development & Director
Aditya Arun Kumar
Gender: male
Year Born:
Founder & Non-Executive Chairperson
Arun Kumar Pillai
Gender: male
Year Born: 1961
MD & Group Chief Executive Officer
Badree Komandur
Gender: male
Year Born: 1972
Executive Vice President of Operations
C. K. Sundar
Gender: male
Year Born:
Senior Vice President of Strides Pharma Inc.
Kevin Cook
Gender: male
Year Born:
Chief Operating Officer
V. S. Ramaraju
Gender: male
Year Born:
Chief Quality Officer
Umesh Kale
Gender: male
Year Born:
Group CFO
Vikesh Kumar
Gender: male
Year Born: 1985
Compliance Officer & Company Secretary
Manjula Ramamurthy
Gender: female
Year Born:
Group Chief Human Resource Officer
Surabhi Loshali
Gender: female
Year Born: 1980
Group General Counsel, Chief Risk Officer & Chief Sustainability Officer
Sormistha Ghosh
Gender: Not Specified
Year Born:
FAQs about Strides Pharma Science Limited
Who is the CEO of the company?
The CEO is Badree Komandur.
What is the current market price of the stock?
The current price is ₹796.25.
What is the 52-week price range?
The range is ₹513.05-1025.
What is the market capitalization of the company?
The market capitalization is ₹7,339.25 crores.
What is the dividend yield?
The dividend yield is 0.50%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 18.47.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Strides Pharma Science Limited (ISIN: INE939A01011) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹7,339.25 crores and an average daily volume of 553,753 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹4.